Retraction Note: Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis (Clinical Rheumatology, (2004), 23, 5, (383-389), 10.1007/s10067-004-0881-z);Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis

Clinical Rheumatology

Volumn 23, Issue 5, 2004, Pages 383-389

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^b   Uzawa, Mitsuyoshi ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitate Hospital   (Japan)

^c Keiyu Orthopaedic Hospital   (Japan)

Author keywords

Alendronate; Bone mineral density (BMD); Cross linked N terminal telopeptides of type I collagen (NTX); Lumbar spine; Metacarpus; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; COLLAGEN TYPE 1; PHOSPHORUS; RISEDRONIC ACID;

ADULT; AGE; AGED; ARTICLE; BACKACHE; BODY MASS; BONE DENSITY; BONE MINERAL; CANCELLOUS BONE; CHRONIC PAIN; CONTROLLED STUDY; CORTICAL BONE; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FACIAL EXPRESSION; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSE; METACARPAL BONE; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN URINE LEVEL; RADIODENSITOMETRY; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VERTEBRA FRACTURE;

EID: 6344232104     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-021-05787-4     Document Type: Erratum

References (25)

1. Shiraki M, Kushida K, Fukunaga M et al. (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 10: 183-192
2. Kushida K, Shiraki M, Nakamura T et al. (2002) The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res 63:9: 606-620
3. Fukunaga M, Kushida K, Kishimoto H et al. (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971-979
4. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488-501
5. Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344-1352
6. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JV (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 85:1895-1900
7. Black DM, Greenspan SL, Ensrud KE et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
8. Black DM, Cummings SR, Karpf DB et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
9. Orimo H, Sugioka Y, Fukunaga M et al. (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139-150.
10. Orimo H, Hayashi Y, Fukunaga M et al. (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
11. Fujita T (1990) Studies of osteoporosis in Japan. Metabolism 39:39-42
12. Orimo H, Fujita T, Onomura T, Inoue T, Kushida K, Shiraki M (1992) Clinical evaluation of Ea-0167 (menatetrenone) in the treatment of osteoporosis: phase III double-blind multicenter comparative study with alfacalcidol. Clin Eval 20:45-100 (in Japanese)
13. Nevitt MC, Thompson DE, Black DM et al. (2000) Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 160:77-85
14. Lorish CD, Maisiak R (1986) The face scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 29:906-909
15. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier P (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 1475-1480
16. Chappard D, Petitjean M, Alexandre C, Vico L, Minaire P, Riffat G (1991) Cortical osteoclasts are less sensitive to etidronate than trabecular osteoclasts. J Bone Miner Res 6:673-680
17. Agarwala S, Sule A, Pai BU, Joshi VR (2002) Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 41:346-347
18. Gangji V, Appelboom T (1999) Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 18:266-267
19. Glover D, Lipton A, Keller A et al. (1994) Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 74:2949-2955
20. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J (2001) Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14:529-533
21. Hortobagyi GN, Terhiault RL, Porter L et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791
22. Siris E, Chines AA, Altman RD et al. (1998) Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 13:1032-1038
23. Pappagallo M, Breuer B, Schneider A, Sperber K (2003) Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage 26:678-683
24. Iwamoto J, Takeda T, Ichimura S (2002) Transient relief of metastatic cancer bone pain by oral administration of etidronate. J Bone Miner Metab 20:228-234
25. Cantatore FP, Acquista CA, Pipitone V (1999) Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 26:2318-2323